{"id":21386,"date":"2025-10-19T07:56:54","date_gmt":"2025-10-19T11:56:54","guid":{"rendered":"https:\/\/citystuff.com\/miami\/2025\/10\/19\/california-to-sell-affordable-state-branded-insulin\/"},"modified":"2025-10-19T07:56:55","modified_gmt":"2025-10-19T11:56:55","slug":"california-to-sell-affordable-state-branded-insulin","status":"publish","type":"post","link":"https:\/\/citystuff.com\/miami\/2025\/10\/19\/california-to-sell-affordable-state-branded-insulin\/","title":{"rendered":"California To Sell Affordable State-Branded Insulin"},"content":{"rendered":"

California to Begin Selling Affordable State-Branded Insulin<\/h1>\n

Introduction to Affordable Insulin<\/h2>\n

California will begin selling affordable insulin under its own label on January 1, nearly three years after Governor Gavin Newsom first announced a partnership to sell state-branded generic drugs at lower prices.
\nBy CHRISTOPHER WEBER
\nLOS ANGELES (AP) \u2014 <\/p>\n

The Partnership and Pricing<\/h2>\n

The nonprofit Civica said it will also distribute its economical diabetes medication to pharmacies nationwide. California began partnering with Civica in 2023 for its \u201cCalRx\u201d brand of insulin and put $50 million toward its development, the company said.
\nStarting in the new year, insulin pens will be available at a recommended price of $11 per pen, or a maximum of $55 for a five-pack, Civica said.<\/p>\n

Access and Affordability<\/h2>\n

\u201cYou don\u2019t need a new prescription,\u201d Newsom said at a news conference in Los Angeles. \u201cIt\u2019s access on the basis of affordability.\u201d
\nIt is one piece of California\u2019s effort to lower prescription drug costs by offering generics as a cheaper alternative. Newsom announced in April that the state will sell the overdose medication Naloxone. The drug, available as a nasal spray and in an injectable form, is considered a key tool in the battle against a nationwide overdose crisis.<\/p>\n

Development and Production<\/h2>\n

For the insulin development, the state entered a 10-year deal with Civica and Biocon Biologics in early 2023. Officials said then that they hoped California\u2019s emergence as an insulin-maker would prompt prices to collapse.
\nThe new pens will be interchangeable with glargine, the generic alternative for more expensive once-a-day injections that regulates blood sugar. As a comparison, the equivalent of a five-pack of Eli Lilly\u2019s Rezvoglar sells to pharmacies for more than $88, according to data compiled by the governor\u2019s office, but consumers may pay a different price based on their insurance.<\/p>\n

Impact and Reception<\/h2>\n

About 38 million Americans \u2014 and roughly 3.5 million Californians \u2014 have diabetes, according to the American Diabetes Association.
\nChris Noble, organizing director of Health Access California, a statewide consumer health care advocacy group, welcomed Newsom\u2019s announcement, saying efforts by California and others to develop a competing generic will bring relief to patients who have seen drug prices spike in recent years.
\n\u201cCalifornia consumers need relief now, so health advocates are relieved to see CalRx moving quickly to lower insulin costs for the people of California while continuing to pursue other needed prescription drug cost solutions,\u201d Noble said in a statement Thursday.<\/p>\n

Potential Risks and Benefits<\/h2>\n

There could be risks. State analysts have warned that California\u2019s entry into the market could prompt other manufacturers to reduce the availability of their drugs, a potential unintended consequence.
\nState lawmakers approved $100 million for the project in 2022, with $50 million dedicated to developing three types of insulin and the rest set aside to invest in a manufacturing facility.
\nAccording to state documents from 2023, the proposed program could save many patients between $2,000 and $4,000 a year. In addition, lower costs could result in substantial savings because the state buys the product every year for the millions of people on its publicly funded health plans.<\/p>\n

Conclusion<\/h2>\n

California’s decision to begin selling affordable state-branded insulin is a significant step towards reducing prescription drug costs and increasing access to essential medications. With the potential to save patients thousands of dollars per year, this initiative has the potential to greatly impact the lives of millions of Californians and Americans living with diabetes.<\/p>\n

FAQs<\/h2>\n